JP2006521378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521378A5 JP2006521378A5 JP2006508789A JP2006508789A JP2006521378A5 JP 2006521378 A5 JP2006521378 A5 JP 2006521378A5 JP 2006508789 A JP2006508789 A JP 2006508789A JP 2006508789 A JP2006508789 A JP 2006508789A JP 2006521378 A5 JP2006521378 A5 JP 2006521378A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- methyl
- inhibitor
- carbonitrile
- tryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- ZADWXFSZEAPBJS-UHFFFAOYSA-N 1-Methyltryptophan Chemical group C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 claims 12
- -1 3-butyl Chemical group 0.000 claims 10
- RUMVKBSXRDGBGO-UHFFFAOYSA-N Indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 claims 6
- 235000002279 indole-3-carbinol Nutrition 0.000 claims 6
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 claims 6
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 5
- 229960001592 Paclitaxel Drugs 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229930003347 taxol Natural products 0.000 claims 5
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 229960004679 Doxorubicin Drugs 0.000 claims 4
- 229960002949 Fluorouracil Drugs 0.000 claims 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims 4
- HOKBIQDJCNTWST-UHFFFAOYSA-N phosphanylidenezinc;zinc Chemical compound [Zn].[Zn]=P.[Zn]=P HOKBIQDJCNTWST-UHFFFAOYSA-N 0.000 claims 4
- AWLWPSSHYJQPCH-VIFPVBQESA-N (2S)-2-amino-3-(6-nitro-1H-indol-3-yl)propanoic acid Chemical compound [O-][N+](=O)C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 AWLWPSSHYJQPCH-VIFPVBQESA-N 0.000 claims 3
- IIQKYWMOMQWBER-UHFFFAOYSA-N 2-amino-3-(1-benzofuran-3-yl)propanoic acid Chemical compound C1=CC=C2C(CC(N)C(O)=O)=COC2=C1 IIQKYWMOMQWBER-UHFFFAOYSA-N 0.000 claims 3
- GAUUPDQWKHTCAX-UHFFFAOYSA-N 2-azaniumyl-3-(1-benzothiophen-3-yl)propanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CSC2=C1 GAUUPDQWKHTCAX-UHFFFAOYSA-N 0.000 claims 3
- KZDNJQUJBMDHJW-UHFFFAOYSA-N 2-azaniumyl-3-(5-bromo-1H-indol-3-yl)propanoate Chemical compound C1=C(Br)C=C2C(CC(N)C(O)=O)=CNC2=C1 KZDNJQUJBMDHJW-UHFFFAOYSA-N 0.000 claims 3
- FSQKKOOTNAMONP-UHFFFAOYSA-N Acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims 3
- 229960004892 Acemetacin Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 3
- 101700006234 AKT1 Proteins 0.000 claims 2
- 229940009456 Adriamycin Drugs 0.000 claims 2
- 229960004562 Carboplatin Drugs 0.000 claims 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 102100010813 EGF Human genes 0.000 claims 2
- 101700033006 EGF Proteins 0.000 claims 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 claims 2
- 229960001842 Estramustine Drugs 0.000 claims 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 Etoposide Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 229960003048 Vinblastine Drugs 0.000 claims 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229960004528 Vincristine Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 101710039033 pkbA Proteins 0.000 claims 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 claims 1
- XFXOLBNQYFRSLQ-UHFFFAOYSA-N 3-aminonaphthalene-2-carboxylic acid Chemical compound C1=CC=C2C=C(C(O)=O)C(N)=CC2=C1 XFXOLBNQYFRSLQ-UHFFFAOYSA-N 0.000 claims 1
- LPAODQAWVMEXKR-UHFFFAOYSA-N 3-propoxy-9H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=NC(OCCC)=C2 LPAODQAWVMEXKR-UHFFFAOYSA-N 0.000 claims 1
- 229940023040 Acyclovir Drugs 0.000 claims 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N DL-tryptophane Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 102000027760 ERBB2 Human genes 0.000 claims 1
- 108010066668 ErbB-2 Receptor Proteins 0.000 claims 1
- 229940022353 Herceptin Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 241001417524 Pomacanthidae Species 0.000 claims 1
- 229960000329 Ribavirin Drugs 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Chemical class 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- 108091006066 receptor inhibitors Proteins 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 claims 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Description
異常な情報伝達により、悪性形質転換、増長そして進行を引起すことがある。その結果、情報伝達経路の阻害剤が、癌治療に使われているのである。過去数年にわたり、多くの情報伝達阻害剤(STIs)が開発されている。腫瘍の成長を抑制するその能力については、現在調査中である。
この出願の発明に関連する先行技術文献情報としては次のものがある。
米国特許第6,482,416号明細書
ローレンス L.ブルトン(Laurence L.Brunton)ら著、「グッドマン及びグリマンによる治療法の薬理学的基準(GOODMAN AND GLIMAN’S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS)」,(米国),第9版,マグロウ−ヒル カンパニー.インク(The McGraw−Hill Companies.Inc.),1996年,p.1295−1296
この出願の発明に関連する先行技術文献情報としては次のものがある。
Claims (17)
- 癌治療用薬学的組成物であって、
少なくとも1つのインドールアミン2,3−ジオキシゲナーゼ(IDO)阻害剤と、
少なくとも1つの情報伝達阻害剤(STI)と
を薬学的に許容される担体媒介物中に有するものである、癌治療用薬学的組成物。 - 請求項1記載の薬学的組成物において、前記少なくとも1つのSTIは、bcr/ablキナーゼ阻害剤、上皮細胞増殖因子(EGF)レセプター阻害剤、her−2/neuレセプター阻害剤、ファルネシルトランスフェラーゼ阻害剤(FTIs)、AktファミリーキナーゼおよびAkt経路の阻害剤、及び細胞周期キナーゼ阻害剤から成る群から選択されるものである。
- 請求項1記載の薬学的組成物において、前記少なくとも1つのSTIは、STI571、SSI−774、C225、ABX−EGF、ハーセプチン、L−744,832、ラパマイシン、LY294002、フラボピリダル、及びUNC−01から成る群から選択されるものである。
- 請求項3記載の薬学的組成物において、前記少なくとも1つのSTIは、L−744,832である。
- 請求項1記載の薬学的組成物において、前記少なくとも1つのIDO阻害剤は、1−メチル−DL−トリプトファン(1MT)、β−(3−ベンゾフラニル)−DL−アラニン、ベータ−(3−ベンゾ(b)チエニル)−DL−アラニン、6−ニトロ−L−トリプトファン、インドール 3−カルビノール、3,3’−ジインドリルメタン、ブラシニン、3,3’−ジインドリルメタン、インドール−3−カルビノール、5−メチル−ブラシニン、エピガロカテキンガレート、5−Br−4−Cl−インドキシル 1,3−ジアセテート、9−ビニルカルバゾール、アセメタシン、5−ブロモ−DL−トリプトファン、5−ブロモインドキシルジアセテート、フェニル−TH−DL−trp、プロペニル−TH−DL−trp、メチル−TH−DL−trp、ブラシレキシン、3−アミノ−2−ナフトエ酸、β−カルボリン、3−ブチル−β−カルボリン、6−フルオロ−3−カルボメトキシ−β−カルボリン、6−イソチオシアネート−3−カルボメトキシ−β−カルボリン、3−プロポキシ−β−カルボリン、3−カルボキシ−β−カルボリン、3−カルボプロポキシ−β−カルボリン、及び3−カルボ−第三−ブトキシ−β−カルボリンから成る群から選択されるものである。
- 請求項1記載の薬学的組成物において、前記少なくとも1つのIDO阻害剤は1−メチル−トリプトファン(1MT)である。
- 慢性ウイルス感染治療用薬学的組成物であって、
少なくとも1つのインドールアミン2,3−ジオキシゲナーゼ(IDO)阻害剤の有効量と、
少なくとも1つの化学療法薬と、
薬学的に許容される担体媒介物と
を有する慢性ウイルス感染治療用薬学的組成物。 - 請求項7記載の薬学的組成物において、前記少なくとも1つのIOD阻害剤は、1−メチル−DL−トリプトファン(1MT)、β−(3−ベンゾフラニル)−DL−アラニン、ベータ−(3−ベンゾ(b)チエニル)−DL−アラニン、6−ニトロ−L−トリプトファン、インドール 3−カルビノール、3,3’−ジインドリルメタン、ブラシニン、3、3’−ジインドールメタン、インドール−3−カルビノール、5−メチル−ブラシニン、エピガロカテチンガレート、5−Br−4−Cl−インドキシル 1,3−ジアセテート、9−ビニルカーバゾール、アセメタシン、5−ブロモ−DL−トリプトファン、5−ブロモインドキシルジアセテート、フェニル−TH−DL−trp、プロペニル−TH−DL−trp、メチル−TH−DL−trp、ブラシレキシン、3−アミノ−2−ナフトエ酸、β−カルボリン、3−ブチル−β−カルボリン、6−フルオロ−3−カルボメトキシ−β−カルボリン、6−イソチオシアネート−3−カルボメトキシ−β−カルボリン、3−プロポキシ−β−カルボリン、3−カルボキシ−β−カルボリン、3−カルボプロポキシ−β−カルボリン、及び3−カルボ−第三−ブトキシ−β−カルボリンから成る群から選択されるものである。
- 請求項8記載の薬学的組成物において、前記少なくとも一つのIDO阻害剤は1−メチル−トリプトファン(1MT)である。
- 請求項7記載の薬学的組成物において、前記少なくとも1つの化学療法薬は、パクリタキセル(Taxol(登録商標))、シスプラチン、ドセタキセル、カルボプラチン、ビンクリスチン、ビンブラスチン、メトトレキサート、シクロホスファミド、CPT−11、5−フルオロウラシル(5−FU)、ゲムシタビン、エストラムスチン、カルムスチン、アドリアマイシン(ドキソルビシン)、エトポシド、三酸化亜ヒ酸、イリノテカン、およびエポチロン誘導体から成る群から選択されるものである。
- 癌治療用薬学的組成物であって、
少なくとも1つのインドールアミン2,3−ジオキシゲナーゼ(IOD)阻害剤の有効量と、
薬学的許容可能な担体と
を有する癌治療用薬学的組成物であり、
前記IDO阻害剤は、フェニル−TH−DL−trp(3−(N−フェニル−チオヒダントイン)−インドール)、プロペニル−TH−DL−trp(3−(N−アリル−チオヒダントイン)−インドール)、及びメチル−TH−DL−trp(3−(N−メチル−チオヒダントイン)−インドール)から成る群から選択されるものである、癌治療用薬学的組成物。 - 癌治療用薬学的組成物であって、
少なくとも1つのインドールアミン2,3−ジオキシゲナーゼ(IDO)阻害剤の有効量と、
少なくとも1つの化学療法薬と
を薬学的に許容される担体媒体中に有するものである、癌治療用薬学的組成物。 - 請求項12記載の薬学的組成物において、前記少なくとも1つの化学療法薬は、パクリタキセル(Taxol(登録商標))、シスプラチン、ドセタキセル、カルボプラチン、ビンクリスチン、ビンブラスチン、メトトレキサート、シクロホスファミド、CPT−11、5−フルオロウラシル(5−FU)、ゲムシタビン、エストラムスチン、カルムスチン、アドリアマイシン(ドキソルビシン)、エトポシド、三酸化亜ヒ酸、イリノテカン、およびエポチロン誘導体から成る群から選択されるものである。
- 請求項13記載の薬学的組成物において、前記少なくとも1つの化学療法薬はパクリタキセルである。
- 請求項12記載の薬学的組成物において、前記少なくとも1つのIOD阻害剤は、1−メチル−DL−トリプトファン(1MT)、β−(3−ベンゾフラニル)−DL−アラニン、ベータ−(3−ベンゾ(b)チエニル)−DL−アラニン、6−ニトロ−L−トリプトファン、インドール 3−カルビノール、3,3’−ジインドールメタン、ブラシニン、3,3’−ジインドリルメタン、インドール−3−カルビノール、5−メチル−ブラシニン、エピガロカテチンガレート、5−Br−4−Cl−インドキシル 1,3−ジアセテート、9−ビニルカルバゾール、アセメタシン、5−ブロモ−DL−トリプトファン、5−ブロモインドキシルジアセテート、フェニル−TH−DL−trp、プロペニル−TH−DL−trp、メチル−TH−DL−trp、ブラシレキシン、3−アミノ−2−ナフトエ酸、β−カルボリン、3−ブチル−β−カルボリン、6−フルオロ−3−カルボメトキシ−β−カルボリン、6−イソチオシアン−3−カルボメトキシ−β−カルボリン、3−プロポキシ−β−カルボリン、3−カルボキシ−β−カルボリン、3−カルボプロポキシ−β−カルボリン、及び3−カルボ−第三−ブトキシ−β−カルボリンから成る群から選択されるものである。
- 請求項15記載の薬学的組成物において、前記少なくとも1つのIDO阻害剤は1−メチル−トリプトファン(1MT)である。
- 請求項7記載の薬学的組成物において、この組成物は、さらに、
アシクロビル、ガングシクロビル、ホスカネット、リバビリン、ヌクレオシド類似体逆転写酵素阻害剤、非ヌクレオシド逆転写酵素阻害剤、及びプロテアーゼ阻害剤から成る群から選択される抗ウイルス物質を含むものである。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45816203P | 2003-03-27 | 2003-03-27 | |
US60/458,162 | 2003-03-27 | ||
US52744903P | 2003-12-05 | 2003-12-05 | |
US60/527,449 | 2003-12-05 | ||
PCT/US2004/005155 WO2004093871A1 (en) | 2003-03-27 | 2004-02-20 | Novel methods for the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006521378A JP2006521378A (ja) | 2006-09-21 |
JP2006521378A5 true JP2006521378A5 (ja) | 2007-04-12 |
JP4921965B2 JP4921965B2 (ja) | 2012-04-25 |
Family
ID=33313373
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006508789A Expired - Fee Related JP4921965B2 (ja) | 2003-03-27 | 2004-02-20 | 癌治療新規方式 |
JP2006508788A Pending JP2006521377A (ja) | 2003-03-27 | 2004-02-20 | 新型ido阻害剤とその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006508788A Pending JP2006521377A (ja) | 2003-03-27 | 2004-02-20 | 新型ido阻害剤とその使用方法 |
Country Status (5)
Country | Link |
---|---|
US (4) | US8008281B2 (ja) |
EP (3) | EP1613308A4 (ja) |
JP (2) | JP4921965B2 (ja) |
CA (2) | CA2520172C (ja) |
WO (2) | WO2004093871A1 (ja) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029310A2 (en) | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
SE0102168D0 (sv) * | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
EP1613308A4 (en) | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US20050186289A1 (en) * | 2003-04-01 | 2005-08-25 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
US7799776B2 (en) | 2004-07-13 | 2010-09-21 | The University Of British Columbia | Indoleamine 2,3-dioxygenase (IDO) inhibitors |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US20060160883A1 (en) * | 2005-01-14 | 2006-07-20 | Stoops Linda M | Regulation of immune system action in mammals through use of a multi-tiered model of immune system function |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
US20090297540A1 (en) * | 2005-10-21 | 2009-12-03 | Andrew Mellor | Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof |
WO2007050963A1 (en) * | 2005-10-27 | 2007-05-03 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
DE102005053947A1 (de) * | 2005-11-11 | 2007-05-16 | Univ Ernst Moritz Arndt | Neue Arzneimittel |
ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
US20090155311A1 (en) * | 2006-01-07 | 2009-06-18 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells |
JP2007320859A (ja) * | 2006-05-30 | 2007-12-13 | Kao Corp | 活性酸素産生酵素発現抑制剤 |
RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
JP2008074744A (ja) * | 2006-09-20 | 2008-04-03 | Kao Corp | 血圧降下剤 |
JP2008074745A (ja) * | 2006-09-20 | 2008-04-03 | Kao Corp | 血糖上昇抑制剤 |
JP2008074742A (ja) * | 2006-09-20 | 2008-04-03 | Kao Corp | 血糖上昇抑制剤 |
WO2009033183A2 (en) * | 2007-09-08 | 2009-03-12 | University Of Florida Research Foundation | Compounds and methods for treatment of hcv and conditions associated with cd81 binding |
JP5583592B2 (ja) * | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ido阻害剤 |
US20110059137A1 (en) * | 2008-03-21 | 2011-03-10 | H. Lee Moffitt Cancer Center And Research Institutute, Inc | Chemokine gene-modified cells for cancer immunotherapy |
WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
SI3320912T1 (sl) | 2008-04-17 | 2021-08-31 | Io Biotech Aps | Imunoterapija na osnovi indolamin 2, 3-dioksigenaze |
CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
US11058699B2 (en) * | 2008-07-01 | 2021-07-13 | Wisconsin Alumni Research Foundation | Method and compositions for inhibition of double stranded DNA viruses |
KR101649548B1 (ko) | 2008-07-08 | 2016-08-19 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸 |
WO2010042685A2 (en) * | 2008-10-08 | 2010-04-15 | Medical College Of Georgia Research Institute, Inc. | Inhibitors of the atb(0,+) transporter and uses thereof |
CA2772760A1 (en) | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
US20100261774A1 (en) * | 2009-02-13 | 2010-10-14 | Children's Hospital Medical Center | Methods for the modulation of Leishmania major infection in mammals |
JP5852557B2 (ja) * | 2009-04-10 | 2016-02-03 | チー,ハイヤン | 新規抗老化剤及びそれらを同定する方法 |
CA2778115C (en) | 2009-10-28 | 2016-04-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
CA2788284A1 (en) * | 2010-02-09 | 2011-08-18 | Georgia Health Sciences University Research Institute, Inc. | Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
CN102370638B (zh) * | 2010-08-20 | 2013-10-23 | 南京大学 | 3,3’-二吲哚甲烷及衍生物在制备治疗肝脏疾病药物中的应用 |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US9847044B1 (en) | 2011-01-03 | 2017-12-19 | Smith & Nephew Orthopaedics Ag | Surgical implement training process |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
NO2694640T3 (ja) | 2011-04-15 | 2018-03-17 | ||
WO2013067142A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Technologies, Inc. | Compounds and treatment methods |
US20130129680A1 (en) * | 2011-11-23 | 2013-05-23 | Thomas Christian Lines | Method for treating hepatitis c virus infection using quercetin-containing compositions |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
US8865772B2 (en) | 2012-07-26 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
RU2015124002A (ru) | 2012-11-20 | 2017-01-10 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы |
EP3366678A1 (en) | 2013-03-14 | 2018-08-29 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
PE20151719A1 (es) | 2013-03-14 | 2015-11-19 | Curadev Pharma Private Ltd | Inhibidores de la ruta de quinurenina |
EP3461493A1 (en) | 2013-03-29 | 2019-04-03 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 antigen peptide conjugate vaccine |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN105764502A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
EP3492094A1 (en) * | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
WO2015031759A1 (en) * | 2013-08-31 | 2015-03-05 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for re-activating epstein-barr virus and screening compounds therefor |
RS60598B1 (sr) | 2013-11-08 | 2020-08-31 | Incyte Holdings Corp | Postupak sinteze inhibitora indolamin 2,3-dioksigenaze |
EP3082802B1 (en) | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
GB201322673D0 (en) * | 2013-12-20 | 2014-02-05 | Tpp Global Dev Ltd | Screening method |
BR112016028255A2 (pt) | 2014-06-06 | 2017-08-22 | Flexus Biosciences Inc | agentes imunorreguladores |
GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
IL250833B (en) | 2014-08-29 | 2022-09-01 | Univ Texas | Administering enzymes to reduce the level of kynurenine in the treatment of tumors |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2016100851A1 (en) | 2014-12-18 | 2016-06-23 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
BR112017019699A2 (pt) * | 2015-03-17 | 2018-09-04 | Pfizer Inc. | derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso |
RU2717577C2 (ru) | 2015-04-21 | 2020-03-24 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Производное имидазоизоиндола, способ его получения и медицинское применение |
JP6515182B2 (ja) * | 2015-05-20 | 2019-05-15 | 大日本住友製薬株式会社 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
JP2018521983A (ja) | 2015-07-16 | 2018-08-09 | バイオカイン セラピューティックス リミテッド | がんを治療するための組成物および方法 |
EP3954369A1 (en) | 2015-07-24 | 2022-02-16 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
CA2998789A1 (en) * | 2015-09-16 | 2017-03-23 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
AU2016335991A1 (en) * | 2015-10-05 | 2018-05-10 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
EP3370773B1 (en) * | 2015-11-04 | 2022-01-05 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
EP3370699A1 (en) | 2015-11-04 | 2018-09-12 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
JP2018532406A (ja) * | 2015-11-09 | 2018-11-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ido1および/またはtdo修飾因子を同定するためのスクリーニングアッセイ |
EP3389783B1 (en) | 2015-12-15 | 2024-07-03 | Merck Sharp & Dohme LLC | Novel compounds as indoleamine 2,3-dioxygenase inhibitors |
US10800780B2 (en) | 2015-12-24 | 2020-10-13 | Genentech, Inc. | TDO2 Inhibitors |
JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
EP3423483A4 (en) | 2016-03-02 | 2019-08-21 | Board Of Regents Of the University Of Texas System | VARIANTS OF HUMAN ENZYME KYNURENINASE HAVING IMPROVED PHARMACOLOGICAL PROPERTIES |
CN109348714A (zh) | 2016-05-04 | 2019-02-15 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
US10633342B2 (en) | 2016-05-04 | 2020-04-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2017192840A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
CN109843293A (zh) | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
KR20190040990A (ko) | 2016-08-26 | 2019-04-19 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
EP3504185B1 (en) * | 2016-08-29 | 2021-11-24 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
EP3515914A4 (en) | 2016-09-24 | 2020-04-15 | BeiGene, Ltd. | NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES |
MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
CN106905256A (zh) * | 2017-03-06 | 2017-06-30 | 中国药科大学 | 苯并五元杂环类ido1抑制剂、其制备方法及应用 |
PT3595660T (pt) * | 2017-03-14 | 2023-09-25 | Sjt Molecular Res Sl | Compostos para utilização na prevenção e/ou tratamento de doença do fígado gordo não-alcoólico e esteato-hepatite nãoalcoólica |
WO2018175954A1 (en) | 2017-03-23 | 2018-09-27 | F. Hoffmann-La Roche Ag | Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors |
US11034661B2 (en) | 2017-03-29 | 2021-06-15 | Merck Sharp & Dohme Corp. | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors |
JP6860237B2 (ja) | 2017-04-24 | 2021-04-21 | 南京薬捷安康生物科技有限公司 | インドールアミン2,3−ジオキシゲナーゼ阻害剤及び適用 |
WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11433143B2 (en) * | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
US11603373B2 (en) | 2017-06-28 | 2023-03-14 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
US11827639B2 (en) | 2017-06-28 | 2023-11-28 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
US12053505B2 (en) | 2017-08-31 | 2024-08-06 | Multimmune Gmbh | Hsp70 based combination therapy |
EP3681498B1 (en) | 2017-09-14 | 2022-10-05 | Lankenau Institute for Medical Research | Methods and compositions for the treatment of cancer |
WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
MX2020007066A (es) | 2018-01-05 | 2020-09-09 | Dicerna Pharmaceuticals Inc | Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia. |
WO2019136112A1 (en) | 2018-01-05 | 2019-07-11 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
TW201938580A (zh) * | 2018-03-08 | 2019-10-01 | 國立大學法人東京大學 | Hmgn部分肽及使用其之癌症療法 |
US20190314324A1 (en) | 2018-04-13 | 2019-10-17 | The University Of Chicago | Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy |
CN112218644A (zh) | 2018-04-16 | 2021-01-12 | 得克萨斯州大学系统董事会 | 人类犬尿氨酸酶及其用途 |
GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
US20210355113A1 (en) | 2018-07-23 | 2021-11-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2020117627A1 (en) | 2018-12-03 | 2020-06-11 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
WO2023225324A1 (en) * | 2022-05-20 | 2023-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating fatty liver and viral infections |
GB202303250D0 (en) | 2023-03-06 | 2023-04-19 | King S College London | Method and compounds |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004183A1 (en) * | 1988-10-07 | 1990-04-19 | Commonwealth Scientific And Industrial Research Organisation | Method for preparation of thiohydantoins and for protein sequence analysis |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US5922689A (en) * | 1995-09-11 | 1999-07-13 | Unitech Pharmaceuticals, Inc. | Cisplatin analogs for cancer treatment |
US5804567A (en) * | 1996-07-18 | 1998-09-08 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method of increasing the effectiveness of anti-metabolites |
IE960761A1 (en) * | 1996-10-31 | 1998-05-06 | Univ Dublin City | Combinations for use in increasing the potency of a¹substrate for multidrug resistance related protein |
US5859190A (en) * | 1997-02-04 | 1999-01-12 | Trega Biosciences, Inc. | Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein |
WO1999029310A2 (en) * | 1997-12-05 | 1999-06-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan and its analogs |
WO2000066764A1 (en) * | 1999-05-03 | 2000-11-09 | Ludwig Institute For Cancer Research | Methods for increasing t cell proliferation |
WO2001028493A2 (en) | 1999-10-15 | 2001-04-26 | President And Fellows Of Harvard College | Small molecule inhibitors of necrosis |
US6756394B1 (en) * | 1999-10-15 | 2004-06-29 | President And Fellow Of Harvard College | Small molecule inhibitors of necrosis |
EP1282445A2 (en) | 2000-03-21 | 2003-02-12 | Atherogenics, Inc. | N-substituted dithiocarbamates for the treatment of biological disorders |
AR033680A1 (es) | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
AU2002211427A1 (en) * | 2000-10-05 | 2002-04-15 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
WO2002053155A1 (en) * | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
IL157740A0 (en) | 2001-03-07 | 2004-03-28 | Incyte San Diego Inc | Heterocyclic derivatives and pharmaceutical compositions containing the same |
CN1444935A (zh) | 2002-05-09 | 2003-10-01 | 华东理工大学 | 表没食子儿茶素没食子酸酯在抗肿瘤药物中应用 |
EP1613308A4 (en) * | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
US7491743B2 (en) * | 2003-08-29 | 2009-02-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
SE526001C2 (sv) | 2003-09-26 | 2005-06-14 | Abb Research Ltd | System för överföring av elektrisk kraft |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
WO2008115804A1 (en) | 2007-03-16 | 2008-09-25 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
-
2004
- 2004-02-20 EP EP04713378A patent/EP1613308A4/en not_active Withdrawn
- 2004-02-20 WO PCT/US2004/005155 patent/WO2004093871A1/en active Application Filing
- 2004-02-20 EP EP04713430A patent/EP1606285A4/en not_active Withdrawn
- 2004-02-20 CA CA2520172A patent/CA2520172C/en not_active Expired - Fee Related
- 2004-02-20 EP EP10075396.1A patent/EP2260846B1/en not_active Expired - Lifetime
- 2004-02-20 US US10/551,151 patent/US8008281B2/en not_active Expired - Lifetime
- 2004-02-20 WO PCT/US2004/005154 patent/WO2004094409A1/en active Application Filing
- 2004-02-20 JP JP2006508789A patent/JP4921965B2/ja not_active Expired - Fee Related
- 2004-02-20 US US10/550,444 patent/US7714139B2/en active Active
- 2004-02-20 CA CA2520586A patent/CA2520586C/en not_active Expired - Fee Related
- 2004-02-20 JP JP2006508788A patent/JP2006521377A/ja active Pending
-
2010
- 2010-04-13 US US12/759,066 patent/US8476454B2/en active Active
-
2011
- 2011-07-20 US US13/186,848 patent/US8383613B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006521378A5 (ja) | ||
JP2006521377A5 (ja) | ||
CA2520586A1 (en) | Novel ido inhibitors and methods of use | |
EP2484678B1 (en) | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors | |
Biersack et al. | Indole compounds against breast cancer: recent developments | |
US5945440A (en) | Indolocarbazole imides and the use thereof | |
CN102015716B (zh) | 用于治疗C-Met酪氨酸激酶介导的疾病的咪唑并[1,2-b]哒嗪衍生物 | |
BRPI0511512A (pt) | derivados pirrolpirimidina úteis no tratamento do cáncer | |
JP2008528469A5 (ja) | ||
NO20071794L (no) | Disubstituerte pyrazolobenzodiazepiner nyttige som inhibitorer for CDK2 og angiogenese, og for behandling av bryst, tarm, lunge og prostata cancer | |
RU2012120288A (ru) | Новые производные нафтиридина и их применение в качестве ингибиторов киназы | |
AR035885A1 (es) | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
BRPI0514295A (pt) | 1, 5-difenilpirazóis | |
Fallah-Tafti et al. | 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities | |
NO20033145D0 (no) | Purinderivater som purinergiske reseptorantagonister | |
BRPI0416557A (pt) | composições de pigmento de pigmento disazo amarelo e pigmento orgánico | |
Akué-Gédu et al. | Kinase inhibitory potencies and in vitro antiproliferative activities of N-10 substituted pyrrolo [2, 3-a] carbazole derivatives | |
EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
MX2007015741A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms. | |
WO2006077024A3 (en) | 5-aminoindole derivatives | |
BRPI0518117A (pt) | uso de um derivado de piridotienopirimidina, composição farmacêutica, método para o tratamento de um sujeito que sofre de uma condição patológica ou doença susceptìvel de cura pela inibição da fosfodiesterase 4 e produto de combinação | |
JP2005511594A5 (ja) | ||
BR0314363A (pt) | Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6 | |
BRPI0411092A (pt) | benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos |